FHTX: Rasio rega marang dodolan Foghorn

Foghorn Therapeutics' price-to-sales ratio is sensitive to global logistics risks and patent disputes in Asia, with 1.10 determining the current level of this parameter. A lack of pricing power due to its pre-commercial status leaves Foghorn Therapeutics dependent on major partners. The efficiency of research into blood cancer genetics is maintained by outsourcing production and testing to external contractors.

FHTX Multiplikator P/S Foghorn Therapeutics Inc. (04.07.2022 - 13.11.2026)

Rincian metrik lan analitis perusahaan Foghorn Therapeutics (FHTX)

- rega saham lan target rega konsensus:

Kurs saham foghorntx.com|FHTX - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Biji pasar Foghorn|FHTX - Nilai Total Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Aset Bersih saben Saham Foghorn Therapeutics|FHTX - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas foghorntx.com|FHTX - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Rasio Kabeh Utang marang Dana Pribadi Foghorn Therapeutics|FHTX - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal foghorntx.com|FHTX - Utang perusahaan|Rasio utang marang aset resik Foghorn|FHTX - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Foghorn Therapeutics|Rasio jangkoan perantara foghorntx.com

- data bathi lan kelipatan valuasi:

FHTX - Penghasilan resik|Bathi resik mangsa ngarep Foghorn Therapeutics|FHTX - Pangali P/E|Pangali mangsa ngarep rega marang bathi foghorntx.com|FHTX - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Foghorn|FHTX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Foghorn Therapeutics|FHTX - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan foghorntx.com|FHTX - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep Foghorn Therapeutics

- rincian pendapatan lan dodolan emiten:

FHTX - Pendapatan lan volume dodolan|Volume dodolan sing dikarepake perusahaan foghorntx.com|FHTX - Kapitalisasi marang pendapatan|Multiplikator Forward P/S Foghorn

Analisis fundamental perusahaan:Foghorn Therapeutics, Inc., FHTX

Foghorn Therapeutics (FHTX) is attracting leading chromatin specialists to develop innovative oncology therapies. The market cap-to-revenue ratio digitizes the value of these intellectual assets, enabling the identification of sustainable price corridors and a real valuation floor through the P/S multiple trend, while eliminating capital freeze risks associated with ignoring currency revaluations and export factors.

Pesaing Foghorn Therapeutics

tgtherapeutics.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ACLX (Arcellx, Inc.)|IRON (Disc Medicine Inc) - Rasio rega marang dodolan|SNDX - Rasio rega marang pendapatan|Rega marang dodolan Kura|ADCT: Multiplikator P/S|Multiplikator rega marang pendapatan vorbio.com VOR|NKTX (Nkarta Inc.) - Multiplikator P/S|COEP: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Actinium Pharmaceuticals Inc (ATNM)|ESLA - Rega marang dodolan|Rasio rega marang pendapatan CASI Pharmaceuticals, Inc. CASI|Rasio kapitalisasi pasar marang pendapatan MRKR|INAB - Rasio rega marang pendapatan|ERNA (Eterna Therapeutics) - Rasio kapitalisasi marang pendapatan|GTBP (GT Biopharma Corp) - Kapitalisasi marang pendapatan|Aptose Biosciences - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BPTH|MEIP (meipharma.com) - Kapitalisasi marang volume dodolan|Multiplikator P/S VINC